ETON Eton Pharmaceuticals, Inc.

Overview and Growth

Eton Pharmaceuticals, Inc. generated $79.95M of revenue in fiscal 2025, with net loss of $4.60M and an operating cash inflow of $10.52M. Revenue of $79.95M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $39.01M in fiscal 2024, revenue recorded a 104.9% year-over-year increase. The company employed $92.11M of total assets, the balance-sheet base supporting its current operating and cash-flow results. Asset turnover was 0.87x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

After reported cost of revenue, the company retained $42.74M as gross profit before recognizing operating expenses and other items. Gross profit represented 53.5% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $844.00K, reflecting costs that exceeded gross profit. Relative to revenue, the operating deficit measured 1.1%, showing the shortfall after operating costs. The company ended the period with a net loss of $4.60M, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 5.8% after all recognized items. The company reported a pretax loss of $4.56M, before the effect of income taxes. The pretax loss equaled 5.7% of revenue, measuring the pre-tax deficit against sales. The company recognized $43.00K of income tax for the period, completing the transition from pretax income to net income. The net loss equaled 17.6% of period-end equity, showing the deficit relative to book capital. Relative to total assets, the net loss represented 5.0%.

Liquidity and Capital Structure

Total assets were $92.11M, supported by $65.96M of liabilities and $26.15M of shareholder equity. At period end, current assets of $60.58M compared with current liabilities of $38.49M, defining the company’s short-term resource position. At 1.57x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Cash and equivalents totaled $25.94M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 67.4%, excluding receivables and other current assets. Borrowings totaled $30.56M, adding a fixed financing obligation alongside the company’s equity capital. The debt-to-equity relationship was 1.17x, showing how much debt the company carried for each unit of book equity. Relative to total assets, debt measured 33.2%, showing how much of the asset base was matched by borrowing. Relative to total assets, liabilities measured 71.6%, complementing the separate equity-based view of the company’s capital structure. Measured against total assets, cash and equivalents represented 28.2%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 21.0% from $76.12M in fiscal 2024, leaving current total assets higher year over year. Against $24.43M of equity in fiscal 2024, the current book-equity balance moved 7.1% and ended higher. The reported cash balance changed 73.7% from $14.94M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

The company reported $10.52M of operating cash flow, a cash inflow that shows the cash generated by operations. The cash-flow statement records $333.00K of capital expenditures, the investment amount considered after operating cash generation. Capital spending absorbed 3.2% of operating cash flow, quantifying the share of cash from operations directed to investment. After capital spending, free cash flow was $10.19M, leaving cash available for debt reduction, shareholder returns, or further investment. Free cash flow represented 12.7% of revenue, linking post-investment cash generation with the company’s operating scale. Measured against total assets, free cash flow represented 11.1%, showing the cash productivity of the company’s assets.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.